Credit Suisse Reiterates Neutral on Verve Therapeutics, Maintains $31 Price Target
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Richard Law has reiterated a Neutral rating on Verve Therapeutics (NASDAQ:VERV) and maintained a $31 price target.
August 11, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Credit Suisse has reiterated a Neutral rating on Verve Therapeutics and maintained a $31 price target.
The reiteration of a Neutral rating by Credit Suisse indicates that the bank does not expect significant price movement in the short term. The maintained price target of $31 suggests that the bank believes the stock is fairly valued at this price. This could lead to a neutral or slightly positive reaction in the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100